Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT02227251Phase 2Active, not recruiting
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Nov 2014
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 2, randomised, open-label trial of selinexor in diffuse large B-cell lymphoma (DLBCL), sponsored by Karyopharm Therapeutics Inc. Primary endpoint: Overall Response Rate at 1 year. Started Nov 2014; status: active, not recruiting.
02
Drugs
selinexor
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02227251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02227251.